<DOC>
	<DOCNO>NCT00772811</DOCNO>
	<brief_summary>Allogeneic Non-Myeloablative Stem Cell Transplantation Using Fludarabine Melphalan Conditioning Regimen Chronic Lymphocytic Leukemia , Lymphoma , Multiple Myeloma</brief_summary>
	<brief_title>Using Fludarabine Melphalan Conditioning Regimen CLL , Lymphoma , Multiple Myeloma</brief_title>
	<detailed_description>Treatment plan - Conditioning chemotherapy infusion allogeneic stem cell include fludarabine 30 mg/m2/day 5 consecutive day ( day -6 -2 ) melphalan 100 mg/m2 day -2 . - Fludarabine Melphalan infuse intravenously 30 minute D5W 100 mL . - Melphalan administer follow completion Fludarabine infusion day -2 . - In case unrelated donor HCT , thymoglobuline 3 mg/kg N/S 500 mL ( le 0.5 mg/mL ) lymphoglobuline 15 mg/kg N/S 500 mL ( le 2 mg/mL ) IV qd day -4 , -3 -2 . Infuse 4 hr . Premedicate Avil 45.5 mg IVP Tylenol 600 mg po . Methylprednisolone 2 mg/kg D5W 100 ml give IV 30 minute thymoglobulin ( lymphoglobuline ) day -4 -2 . - Before administration melphalan , prehydration do intravenously 0.9 % NS 1L 3 hour . - 30 minute melphalan infusion , premedication dexamethasone 10 mg ativan 1 mg i.v . push give . Appropriate antiemetic ondansetron 8 mg i.v . push every 4-6 hour ativan 1-2 mg i.v . push every 4-6 hour administer . - Hydration 0.9 % NS 80 mL/hour administer least 7 day . Appropriate amount KCl mixed . - GVHD prophylaxis include cyclosporine A ( CSA ) methotrexate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must 15 year age old 65 year age young Patients CLL , lymphoma , multiple myeloma include study No prior anticancer treatment do within 30 day . Informed consent give . Patients HLAidentical single HLAlocus mismatch donor . Karnofsky performance scale 50 ( see Appendix I ) . Patients must psychiatric disorder mental deficiency severe make compliance stem cell transplant treatment unlike , make informed consent impossible . Patients high serum creatinine level exclude . Patients uncontrolled infection . No major anticipate illness organ failure incompatible survival stem cell transplant . Serum bilirubin less equal 4.0 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>